Li Weidong, Chen Cihui, Saud Shakir M, Geng Liang, Zhang Ge, Liu Rui, Hua Baojin
Oncology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
BMC Complement Altern Med. 2014 May 12;14:153. doi: 10.1186/1472-6882-14-153.
Lung cancer is one of the leading causes of cancer-related mortality worldwide. Conventional chemotherapy and radiotherapy are the primary therapeutic methods for lung cancer with the use of combination therapies gaining popularity. The frequency and duration of treatment, as well as, managing lung cancer by targeting multiple aspects of cancer biology is often limited by toxicity to the patient. There are many naturally occurring anticancer agents that have a high degree of efficacy and low toxicity, offering a viable and safe approach for the treatment of lung cancer. The herbs traditionally used in Chinese medicine for anticancer treatment offer great potential to enhance the efficacy of conventional therapy. In this study, we evaluated the synergistic effects of Fei-Liu-Ping (FLP) ointment in treating lung cancer; a known anticancer Chinese herbal based formula.
In this study, A549 human lung carcinoma cell line and Lewis lung carcinoma xenograft mouse model were used. In addition, we utilized an in vitro co-culture system to simulate the tumor microenvironment in order to evaluate the molecular mechanisms of FLP treatment.
FLP treatment significantly inhibited tumor growth in the Lewis lung xenograft by 40 percent, compared to that of cyclophosphamide (CTX) of 62.02 percent. Moreover, combining FLP and CTX inhibited tumor growth by 83.23 percent. Upon evaluation, we found that FLP treatment reduced the concentration of serum pro-inflammatory cytokines IL-6, TNF-α, and IL-1β. In addition, we also found an improvement in E-cadherin expression and inhibition of N-cadherin and MMP9. We found similar findings in vitro when we co-cultured A549 cells with macrophages. FLP treatment inhibited A549 cell growth, invasion and metastasis, in part, through the regulation of NF-κB and altering the expression of E-cadherin, N-cadherin, MMP2 and MMP9.
FLP exerts anti-inflammatory properties in the tumor microenvironment, which may contribute to its anticancer effects. FLP treatment may be a promising therapy for inflammation associated lung cancer treatment alone, or in combination with conventional therapies and may prevent lung cancer metastasis.
肺癌是全球癌症相关死亡的主要原因之一。传统化疗和放疗是肺癌的主要治疗方法,联合疗法也越来越受欢迎。治疗的频率和持续时间,以及通过针对癌症生物学的多个方面来治疗肺癌,常常受到对患者毒性的限制。有许多天然存在的抗癌药物具有高度的疗效和低毒性,为肺癌治疗提供了一种可行且安全的方法。传统用于抗癌治疗的中药具有极大潜力来提高传统疗法的疗效。在本研究中,我们评估了肺瘤平(FLP)软膏治疗肺癌的协同作用;这是一种已知的基于中药的抗癌配方。
在本研究中,使用了A549人肺癌细胞系和Lewis肺癌异种移植小鼠模型。此外,我们利用体外共培养系统来模拟肿瘤微环境,以评估FLP治疗的分子机制。
与环磷酰胺(CTX)的62.02%相比,FLP治疗显著抑制了Lewis肺癌异种移植瘤的生长,抑制率为40%。此外,联合使用FLP和CTX抑制肿瘤生长的比例为83.23%。经评估,我们发现FLP治疗降低了血清促炎细胞因子IL-6、TNF-α和IL-1β的浓度。此外,我们还发现E-钙黏蛋白表达有所改善,N-钙黏蛋白和MMP9受到抑制。当我们将A549细胞与巨噬细胞共培养时,在体外也发现了类似的结果。FLP治疗部分通过调节NF-κB以及改变E-钙黏蛋白、N-钙黏蛋白、MMP2和MMP9的表达来抑制A549细胞的生长、侵袭和转移。
FLP在肿瘤微环境中发挥抗炎特性,这可能有助于其抗癌作用。FLP治疗可能是一种有前景的治疗方法,可单独用于治疗与炎症相关的肺癌,或与传统疗法联合使用,并且可能预防肺癌转移。